Loading
companiesCompany
Immunome
Immunome is a US biotechnology company whose lead drug varegacestat, a gamma-secretase inhibitor acquired with Ayala Pharmaceuticals, completed the phase 3 RINGSIDE trial in progressing desmoid tumours; it also develops antibody-drug conjugates.
Also called: Immunome, Inc.Ayala Pharmaceuticals
Overview
Immunome, headquartered in Bothell, Washington, develops targeted cancer therapies. Its most advanced programme is varegacestat (AL102), an oral gamma-secretase inhibitor that blocks Notch signalling and was tested against placebo in the phase 3 RINGSIDE trial in adults and adolescents with progressing desmoid tumours; the programme came with the acquisition of Ayala Pharmaceuticals' assets. The company also develops antibody-drug conjugates from its own antibody discovery platform. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Bothell, WA, US
Scorecard
All companies#442of 1244 companies, score 7
- phase 3 +3
- modalities +2
- registry trials +2
0 approved, 1 in phase 3, 0 earlier, 0 targets, 1 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Phase 3small molecule
Varegacestat is an experimental small-molecule drug from Immunome in phase 3 trials for desmoid tumour, with its target not yet stated publicly.
Similar pages
- TreatmentNirogacestat
Shares Gamma-secretase (PSEN1), Desmoid tumour.
cancers
fronts
targets
drugs
Phase 3small molecule